SANGAMO THERAPEUTICS, INC Logo

SANGAMO THERAPEUTICS, INC

Developing genomic cures for severe genetic diseases using proprietary zinc finger technology.

SGMO | US

Overview

Corporate Details

ISIN(s):
US8006771062
LEI:
Country:
United States of America
Address:
501 CANAL BLVD., 94084 RICHMOND
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company focused on translating groundbreaking science into transformative medicines. The company utilizes its proprietary zinc finger technology platform to develop potential genomic cures for patients suffering from severe diseases where current options only manage symptoms. Sangamo's research and development efforts are centered on gene therapy, cell therapy, in vivo genome editing, and gene regulation. The company's pipeline targets a range of genetic disorders, including hemophilia and Fabry disease, and it has engaged in collaborations with partners like Pfizer to advance its therapeutic programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all SANGAMO THERAPEUTICS, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SANGAMO THERAPEUTICS, INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SANGAMO THERAPEUTICS, INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America
ICCC
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America
IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea
424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America
IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan
4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America
IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America
IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America
IMRN
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO

Talk to a Data Expert

Have a question? We'll get back to you promptly.